Literature DB >> 19191556

Stereoselective synthesis of chiral IBR2 analogues.

Xiao-Long Qiu1, Jiewen Zhu, Guikai Wu, Wen-Hwa Lee, A Richard Chamberlin.   

Abstract

Two stereoselective routes were developed to synthesize optically pure IBR2 analogues 1-16. The first features addition of N-Boc-3-bromoindole 26 to the sulfinamide 25, providing a 1:1 ratio of the separable diasteroisomers 27 and 28 in good yield. In a straightforward fashion, the sulfinamides 27 and 28 were conveniently converted into the key amines 39 and 47 over 8 steps, respectively, from which a series of 3,4-dihydroisoquinolinyl IBR2 analogues 1-14 containing fluorinated and trifluoromethylated benzyl groups were prepared. Another route highlights the highly enantioselective addition of indole to the sulfonyl amide 50 with bifunctional aminothioureas 57 and 58 as catalysts. After the reaction conditions were optimized, the desired sulfonyl amides (R)-55 and (S)-55 were obtained in 99% ee and 98% ee, respectively. Acylation of (R)-55 and (S)-55 separately and subsequent allylation gave compounds 60 and 63, respectively, which were further subjected to RCM to furnish compounds 61 and 64 and, after removal of the Boc groups, the desired IBR2 analogues 15 and 16.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191556     DOI: 10.1021/jo802607f

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors.

Authors:  Jiewen Zhu; Hongyuan Chen; Xuning Emily Guo; Xiao-Long Qiu; Chun-Mei Hu; A Richard Chamberlin; Wen-Hwa Lee
Journal:  Eur J Med Chem       Date:  2015-04-09       Impact factor: 6.514

2.  Copper-catalyzed aerobic decarboxylative coupling between cyclic α-amino acids and diverse C-H nucleophiles with low catalyst loading.

Authors:  Jing Guo; Ying Xie; Qiao-Lei Wu; Wen-Tian Zeng; Albert S C Chan; Jiang Weng; Gui Lu
Journal:  RSC Adv       Date:  2018-05-01       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.